BRAF V600EBiomarker (exploratory)ESMO 2025來源:人工整理
EC+mFOLFOX6 vs EC vs SOC
關鍵結果C2D15 D/ND: 67.1% vs 45.2% vs 37.5%; resistance 6.6% vs 37.9%
化療骨幹壓制抗藥性克隆——EC+chemo 優於 EC alone 的分子機制
詳細證據整理
Circulating Tumor (ct)DNA Analysis of BRAF V600E Dynamics and Changes in Genomic Landscape in Patients with First-Line BRAF V600E-Mutant mCRC Treated in BREAKWATER
Key Findings
ctDNA vs Tissue Concordance
Concordance between ctDNA-based and tissue-based BRAF V600E detection was 87.4%.
Baseline BRAF V600E VAF and Outcomes
EC+mFOLFOX6 demonstrated ORR and OS benefit independent of baseline BRAF V600E variant allele frequency (VAF), indicating that the treatment effect was consistent regardless of baseline ctDNA levels.
ctDNA Dynamics at Cycle 2, Day 15 (C2D15)
Detected-to-Not Detected (D/ND) conversion rates at C2D15 by treatment arm:
| Arm | D/ND Conversion Rate |
|---|---|
| EC+mFOLFOX6 | 67.1% |
| EC alone | 45.2% |
| Control (SOC) | 37.5% |
Prognostic Value of ctDNA Clearance
Patients who achieved D/ND conversion (ctDNA clearance) had substantially improved outcomes:
- Median OS = Not Estimable (NE) for D/ND patients
- HR 0.30 vs patients who remained D/D (detected/detected)
Resistance Mutations at Cycle 7, Day 1 (C7D1)
Emergence of resistance mutations differed significantly by treatment arm:
| Arm | Resistance Mutations at C7D1 |
|---|---|
| EC+mFOLFOX6 | 6.6% |
| EC alone | 37.9% |
These findings suggest that the addition of chemotherapy to EC significantly delays the emergence of resistance mutations, potentially explaining the superior duration of response and survival seen with the triplet combination.
本頁僅供醫療專業人員教育與臨床參考,不構成醫療建議;臨床決策請以原始文獻與現行指引為準。
讀者討論
讀者留言是個人意見,不是本站的文獻整理,也沒有經過醫學審核。
載入留言中…